Description
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Mubritinib, Free Base
Product ID M8007
Cas No. 366017-09-6
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 366017-09-6 |
|---|---|
| Purity | ≥98% |
| Formula | C25H23F3N4O2 |
| Formula Wt. | 468.47 |
| Chemical Name | 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole |
| IUPAC Name | 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4- (trifluoromethyl)phenyl]ethenyl]-1,3-oxazole |
| Synonym | TAK-165 |
| Appearance | White to off white powder |
Shipping and Storage
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Nagasawa J, Mizokami A, Koshida K, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006 May;13(5):587-92. PMID: 16771730.